Supplementary Figure 1 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer

Key Points

Comparing the tumor microenvironment reveals differences between colorectal cancer liver and lung metastases.
Key findings suggest nivolumab and relatlimab could affect tumor response in diverse environments.
Analysis of metastatic sites shows unique characteristics of the tumor microenvironment in colorectal cancer.
Understanding tumor microenvironment variations is crucial for improving treatment strategies for patients.

Supplementary Figure compares tumor microenvironment in colorectal cancer liver and lung metastases, highlighting treatment implications.

Supplementary Figure 1. Comparison of the tumor microenvironment (TME) between colorectal cancer (CRC) liver and lung metastases.

No takes yet. Share an insight, caveat, or question.

Christenson et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share